Wedbush Reaffirms “Outperform” Rating for Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a report issued on Thursday, Benzinga reports. They currently have a $165.00 price objective on the stock. Wedbush’s target price indicates a potential upside of 93.01% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and set a $120.00 price objective on shares of Oruka Therapeutics in a research note on Thursday. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Mizuho set a $120.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, September 3rd. Guggenheim reiterated a “buy” rating and set a $200.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Finally, Piper Sandler reiterated an “overweight” rating and set a $180.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $128.91.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock traded down $4.44 during trading on Thursday, reaching $85.49. The company had a trading volume of 1,294,347 shares, compared to its average volume of 1,104,061. Oruka Therapeutics has a 12-month low of $14.89 and a 12-month high of $115.51. The stock’s 50 day moving average price is $96.79 and its two-hundred day moving average price is $75.32. The firm has a market capitalization of $5.66 billion, a price-to-earnings ratio of -42.11 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, research analysts expect that Oruka Therapeutics will post -2.42 earnings per share for the current year.

Insider Transactions at Oruka Therapeutics

In other news, CEO Lawrence Klein sold 75,000 shares of the business’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $91.83, for a total transaction of $6,887,250.00. Following the transaction, the chief executive officer directly owned 925,580 shares of the company’s stock, valued at approximately $84,996,011.40. The trade was a 7.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total transaction of $734,143.86. Following the transaction, the insider directly owned 31,771 shares in the company, valued at approximately $2,935,004.98. The trade was a 20.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 122,950 shares of company stock valued at $11,528,806. Corporate insiders own 23.49% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Algert Global LLC raised its holdings in Oruka Therapeutics by 3.5% in the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock valued at $512,000 after acquiring an additional 180 shares in the last quarter. Nykredit A S acquired a new stake in Oruka Therapeutics in the second quarter valued at $29,000. AlphaCentric Advisors LLC raised its holdings in Oruka Therapeutics by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after acquiring an additional 626 shares in the last quarter. Orion Capital Management LLC acquired a new stake in Oruka Therapeutics in the second quarter valued at $91,000. Finally, PNC Financial Services Group Inc. raised its holdings in Oruka Therapeutics by 119.7% in the first quarter. PNC Financial Services Group Inc. now owns 3,186 shares of the company’s stock valued at $156,000 after acquiring an additional 1,736 shares in the last quarter. 56.44% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Oruka reported that its ORKA-001 psoriasis therapy produced deeper responses through Week 28 in the Phase 2a EVERLAST-A trial without additional dosing. PASI 100 increased to 71.4% and PASI 90 to 87.3%, while patients who crossed over from placebo achieved similar response rates. The company said ORKA-001 maintained a favorable safety and tolerability profile. Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001
• Positive Sentiment: UBS described ORKA-001’s psoriasis treatment profile as competitive following the new clinical data, supporting the potential for durable efficacy and reinforcing investor interest in Oruka’s pipeline. Oruka Therapeutics Psoriasis Treatment Maintains Competitive Profile
• Positive Sentiment: Analysts remain bullish: Wedbush reaffirmed an Outperform rating with a $165 price target, while HC Wainwright reiterated Buy with a $120 target. Other coverage also highlights Oruka among attractive healthcare stocks. Analysts Are Bullish on Oruka Therapeutics
• Neutral Sentiment: Oruka also provided progress on the randomized, double-blind, placebo-controlled ORKA-002 study in hidradenitis suppurativa. The update expands the pipeline opportunity, but the study remains clinical-stage and does not yet establish efficacy. ORKA-002 Trial Progress
• Negative Sentiment: The stock fell after the psoriasis update even though efficacy improved. Reports indicate that safety disclosures may have offset the positive results, while investors may also be taking profits or demanding more complete data. Full 52-week EVERLAST-A results are expected in December 2026, leaving additional clinical risk ahead. ORKA Stock Down Despite Positive Week 28 Data

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ:ORKA) is a clinical-stage biotechnology company developing long-acting monoclonal antibody therapies for immune-mediated diseases. The company’s research is focused on creating medicines that may allow less frequent dosing than existing biologic treatments.

Oruka’s initial development programs are aimed at inflammatory conditions, including psoriasis. Its pipeline includes engineered antibody candidates designed to target important immune pathways, including interleukin-23 and interleukin-17.